TOP HEADLINES

Featured Story

LabCorp and CareDx call it quits on partnership to develop lupus test

LabCorp and CareDx have officially pulled the plug on a previously announced agreement to develop a lupus flare predictor test after completing the first phase of their collaboration.

Indian startup develops low-cost, portable Dx for developing countries

Amid growing demand for portable, low-cost diagnostics, Indian startup Swasthya Slate is developing a device that could help reduce costs and improve outcomes for patients in developing countries.

Illumina and bioMérieux to develop innovative sequencing system for infectious diseases

As the diagnostics industry explores innovative ways to monitor and contain bacterial infections, Illumina is joining forces with French diagnostic outfit bioMérieux to develop a next-generation sequencing system that can identify infectious bacteria in service labs and hospitals.

Illumina teams up with Broad Institute, USAID for Ebola tracking

Illumina is lending a hand to Ebola diagnostic efforts, teaming up with U.S. government officials and researchers at the Broad Institute to help scientists in West Africa track the virus and develop new tools to prevent its spread.

Illumina, Sequenta partner up on next-gen cancer diagnostic

Coming off a huge third quarter for revenue growth, genomic sequencing outfit Illumina this week inked a deal with Sequenta to commercialize a diagnostics kit that detects a condition associated with cancer remission.

MORE NEWS

From Our Sister Sites

FierceBiotech

High profile U.K. investor Neil Woodford made headlines last week when he invested $25 million into Northwest Biotherapeutics, and that's a sign of much more to come, according to reports, as the ex-Invesco manager is planning to unveil a new fund devoted solely to emerging biotechs.

FiercePharma Manufacturing

NewLink Genetics, the small Iowa company working on a promising Ebola vaccine, has been looking for manufacturing muscle, not to mention development experience and marketing know-how, to get its Ebola vaccine to market.